Vivos Therapeutics (VVOS) EBITDA Margin (2020 - 2026)
Vivos Therapeutics' (VVOS) quarterly EBITDA Margin came in at 128.67% in Q1 2026, up 124.0% year-on-year from 57.44% in Q1 2025, and up 22.9% on a QoQ basis from 166.89% in Q4 2025.
Vivos Therapeutics (VVOS) EBITDA Margin (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 7 years of EBITDA Margin data on file, last reported at 128.67% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 124.0% year-over-year to 128.67% in Q1 2026; TTM through Mar 2026 was 115.47%, a 3819.0% decrease from a year earlier, with the FY2025 full-year figure at 114.05%, down 3973.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 128.67%, up from 166.89% in the prior quarter.
- Over the last five years, EBITDA Margin for VVOS reached as high as 47.76% in Q2 2024 and fell as low as 182.19% in Q1 2022.
- Historically, EBITDA Margin has averaged 120.9% across 5 years, with a median of 127.36% in 2025.
- Across the five-year window, EBITDA Margin soared 8529 bps in 2024 and tumbled 9101 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 153.49% in 2022, then grew by 17 bps to 127.25% in 2023, then jumped by 40 bps to 75.88% in 2024, then slumped by 120 bps to 166.89% in 2025, then gained by 23 bps to 128.67% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 128.67% in Q1 2026, 166.89% in Q4 2025, and 69.79% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.88 Bn | 176.59 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 128.94 Bn | 126.06 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 108.75 Bn | 99.53 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 68.65 Bn | 67.19 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 48.22 Bn | 44.55 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 28.43 Bn | 27.31 Bn | 750.30 Mn | 21.42% |
| 7 | GE HealthCare Technologies | 28.32 Bn | 26.03 Bn | 1.98 Bn | 10.04% |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.10 Bn | 21.98 Bn | 2.07 Bn | 6.17% |
| 10 | Vivos Therapeutics | 5.71 Mn | 3.60 Mn | 3.06 Mn | -128.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.67% |
| Dec 31, 2025 | -166.89% |
| Sep 30, 2025 | -69.79% |
| Jun 30, 2025 | -127.36% |
| Mar 31, 2025 | -129.91% |
| Dec 31, 2024 | -75.88% |
| Sep 30, 2024 | -68.52% |
| Jun 30, 2024 | -47.76% |
| Mar 31, 2024 | -110.70% |
| Dec 31, 2023 | -127.25% |
| Sep 30, 2023 | -110.27% |
| Jun 30, 2023 | -133.05% |
| Mar 31, 2023 | -129.76% |
| Dec 31, 2022 | -153.49% |
| Sep 30, 2022 | -127.34% |
| Jun 30, 2022 | -166.44% |
| Mar 31, 2022 | -182.19% |
| Dec 31, 2021 | -168.66% |
| Sep 30, 2021 | -121.05% |
| Jun 30, 2021 | -90.30% |